Annual SG&A
$481.87 M
+$30.45 M+6.75%
31 December 2023
Summary:
Sarepta Therapeutics annual selling, general & administrative expenses is currently $481.87 million, with the most recent change of +$30.45 million (+6.75%) on 31 December 2023. During the last 3 years, it has risen by +$164.00 million (+51.59%). SRPT annual SG&A is now at all-time high.SRPT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$128.20 M
-$10.60 M-7.63%
30 September 2024
Summary:
Sarepta Therapeutics quarterly selling, general & administrative expenses is currently $128.20 million, with the most recent change of -$10.60 million (-7.63%) on 30 September 2024. Over the past year, it has increased by +$7.31 million (+6.04%). SRPT quarterly SG&A is now -16.92% below its all-time high of $154.32 million, reached on 30 June 2022.SRPT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$17.63 B
+$121.84 M+0.69%
30 September 2024
Summary:
Sarepta Therapeutics TTM selling, general & administrative expenses is currently -$17.63 billion, with the most recent change of +$121.84 million (+0.69%) on 30 September 2024. Over the past year, it has dropped by -$18.10 billion (-3845.88%). SRPT TTM SG&A is now -135515.11% below its all-time high of $525.70 million, reached on 30 September 2024.SRPT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.8% | +6.0% | -3845.9% |
| 3 y3 years | +51.6% | +109.7% | -6165.7% |
| 5 y5 years | +131.9% | +70.0% | -6743.1% |
SRPT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.5% | -16.9% | +109.7% | -47.8% | +1.0% |
| 5 y | 5 years | at high | +131.9% | -16.9% | +109.7% | -144.0% | +1.0% |
| alltime | all time | at high | >+9999.0% | -16.9% | >+9999.0% | <-9999.0% | +1.0% |
Sarepta Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $128.20 M(-7.6%) | $525.70 M(+1.4%) |
| June 2024 | - | $138.80 M(+9.3%) | $518.39 M(+4.1%) |
| Mar 2024 | - | $127.00 M(-3.6%) | $498.16 M(+3.4%) |
| Dec 2023 | $481.87 M(+6.7%) | $131.70 M(+8.9%) | $481.87 M(+2.4%) |
| Sept 2023 | - | $120.89 M(+2.0%) | $470.65 M(+3.5%) |
| June 2023 | - | $118.56 M(+7.1%) | $454.54 M(-7.3%) |
| Mar 2023 | - | $110.71 M(-8.1%) | $490.30 M(+8.6%) |
| Dec 2022 | $451.42 M(+59.7%) | $120.48 M(+15.0%) | $451.42 M(+10.4%) |
| Sept 2022 | - | $104.79 M(-32.1%) | $409.00 M(+12.0%) |
| June 2022 | - | $154.32 M(+114.8%) | $365.34 M(+28.9%) |
| Mar 2022 | - | $71.84 M(-8.0%) | $283.37 M(+0.3%) |
| Dec 2021 | $282.66 M(-11.1%) | $78.06 M(+27.7%) | $282.66 M(-2.7%) |
| Sept 2021 | - | $61.13 M(-15.5%) | $290.65 M(-4.7%) |
| June 2021 | - | $72.35 M(+1.7%) | $304.90 M(-0.4%) |
| Mar 2021 | - | $71.13 M(-17.3%) | $306.24 M(-3.7%) |
| Dec 2020 | $317.88 M(+11.6%) | $86.05 M(+14.2%) | $317.88 M(+1.5%) |
| Sept 2020 | - | $75.37 M(+2.3%) | $313.25 M(-0.0%) |
| June 2020 | - | $73.69 M(-11.0%) | $313.31 M(+2.1%) |
| Mar 2020 | - | $82.77 M(+1.7%) | $307.01 M(+7.8%) |
| Dec 2019 | $284.81 M(+37.1%) | $81.42 M(+7.9%) | $284.81 M(+7.3%) |
| Sept 2019 | - | $75.43 M(+11.9%) | $265.39 M(+9.2%) |
| June 2019 | - | $67.39 M(+11.3%) | $243.00 M(+8.0%) |
| Mar 2019 | - | $60.57 M(-2.3%) | $224.99 M(+8.3%) |
| Dec 2018 | $207.76 M(+69.3%) | $62.00 M(+16.9%) | $207.76 M(+15.1%) |
| Sept 2018 | - | $53.04 M(+7.4%) | $180.57 M(+16.0%) |
| June 2018 | - | $49.38 M(+13.9%) | $155.71 M(+11.2%) |
| Mar 2018 | - | $43.34 M(+24.5%) | $139.98 M(+13.9%) |
| Dec 2017 | $122.68 M(+51.1%) | $34.81 M(+23.5%) | $122.85 M(+12.6%) |
| Sept 2017 | - | $28.18 M(-16.3%) | $109.07 M(+5.8%) |
| June 2017 | - | $33.65 M(+28.4%) | $103.08 M(+18.4%) |
| Mar 2017 | - | $26.22 M(+24.7%) | $87.06 M(+6.5%) |
| Dec 2016 | $81.20 M(+8.2%) | $21.03 M(-5.2%) | $81.72 M(-3.9%) |
| Sept 2016 | - | $22.18 M(+25.8%) | $85.03 M(+9.1%) |
| June 2016 | - | $17.64 M(-15.5%) | $77.93 M(+6.4%) |
| Mar 2016 | - | $20.88 M(-14.2%) | $73.22 M(-2.4%) |
| Dec 2015 | $75.04 M(+52.2%) | $24.33 M(+61.2%) | $75.04 M(+16.1%) |
| Sept 2015 | - | $15.09 M(+16.7%) | $64.63 M(+3.5%) |
| June 2015 | - | $12.93 M(-43.0%) | $62.42 M(+1.2%) |
| Mar 2015 | - | $22.70 M(+63.1%) | $61.71 M(+25.1%) |
| Dec 2014 | $49.31 M(+56.1%) | $13.92 M(+8.0%) | $49.31 M(+7.7%) |
| Sept 2014 | - | $12.88 M(+5.5%) | $45.80 M(+11.9%) |
| June 2014 | - | $12.21 M(+18.5%) | $40.93 M(+14.4%) |
| Mar 2014 | - | $10.30 M(-0.9%) | $35.77 M(+13.2%) |
| Dec 2013 | $31.59 M(+116.0%) | $10.40 M(+29.8%) | $31.59 M(+21.2%) |
| Sept 2013 | - | $8.01 M(+13.6%) | $26.06 M(+20.6%) |
| June 2013 | - | $7.05 M(+15.1%) | $21.61 M(+23.7%) |
| Mar 2013 | - | $6.13 M(+25.8%) | $17.48 M(+19.5%) |
| Dec 2012 | $14.63 M(-8.9%) | $4.87 M(+36.6%) | $14.63 M(+7.2%) |
| Sept 2012 | - | $3.56 M(+22.3%) | $13.64 M(+2.9%) |
| June 2012 | - | $2.92 M(-11.2%) | $13.27 M(-7.3%) |
| Mar 2012 | - | $3.28 M(-15.5%) | $14.31 M(-10.9%) |
| Dec 2011 | $16.05 M(+11.6%) | $3.88 M(+21.9%) | $16.05 M(+3.3%) |
| Sept 2011 | - | $3.19 M(-19.6%) | $15.54 M(-1.6%) |
| June 2011 | - | $3.96 M(-21.2%) | $15.79 M(-4.7%) |
| Mar 2011 | - | $5.03 M(+49.4%) | $16.56 M(+15.2%) |
| Dec 2010 | $14.38 M | $3.37 M(-2.2%) | $14.38 M(+6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | $3.44 M(-27.3%) | $13.49 M(+13.8%) |
| June 2010 | - | $4.73 M(+66.4%) | $11.85 M(+27.1%) |
| Mar 2010 | - | $2.84 M(+15.1%) | $9.32 M(+7.2%) |
| Dec 2009 | $8.70 M(-24.2%) | $2.47 M(+37.2%) | $8.70 M(-19.8%) |
| Sept 2009 | - | $1.80 M(-18.4%) | $10.84 M(-11.2%) |
| June 2009 | - | $2.21 M(-0.6%) | $12.22 M(+0.2%) |
| Mar 2009 | - | $2.22 M(-51.9%) | $12.19 M(-2.7%) |
| Dec 2008 | $11.47 M(+22.9%) | $4.62 M(+45.4%) | $12.53 M(+33.8%) |
| Sept 2008 | - | $3.17 M(+45.3%) | $9.36 M(+21.1%) |
| June 2008 | - | $2.18 M(-14.5%) | $7.73 M(+2.0%) |
| Mar 2008 | - | $2.55 M(+75.7%) | $7.58 M(-18.8%) |
| Dec 2007 | $9.33 M(+20.4%) | $1.45 M(-5.9%) | $9.33 M(-6.2%) |
| Sept 2007 | - | $1.54 M(-23.9%) | $9.95 M(+2.0%) |
| June 2007 | - | $2.03 M(-52.8%) | $9.75 M(+5.6%) |
| Mar 2007 | - | $4.30 M(+108.1%) | $9.23 M(+19.1%) |
| Dec 2006 | $7.75 M(+49.6%) | $2.07 M(+53.5%) | $7.75 M(+9.3%) |
| Sept 2006 | - | $1.35 M(-11.1%) | $7.09 M(+4.3%) |
| June 2006 | - | $1.52 M(-46.3%) | $6.80 M(+3.7%) |
| Mar 2006 | - | $2.82 M(+100.2%) | $6.56 M(+26.5%) |
| Dec 2005 | $5.18 M(+9.4%) | $1.41 M(+33.9%) | $5.18 M(-0.1%) |
| Sept 2005 | - | $1.05 M(-17.3%) | $5.19 M(+1.7%) |
| June 2005 | - | $1.27 M(-12.2%) | $5.10 M(+3.2%) |
| Mar 2005 | - | $1.45 M(+2.2%) | $4.95 M(+4.4%) |
| Dec 2004 | $4.74 M(+3.9%) | $1.42 M(+46.9%) | $4.74 M(+12.6%) |
| Sept 2004 | - | $964.70 K(-13.6%) | $4.21 M(-12.4%) |
| June 2004 | - | $1.12 M(-9.9%) | $4.80 M(-1.3%) |
| Mar 2004 | - | $1.24 M(+39.4%) | $4.86 M(+6.7%) |
| Dec 2003 | $4.56 M(+21.1%) | $888.40 K(-43.1%) | $4.56 M(+2.6%) |
| Sept 2003 | - | $1.56 M(+32.5%) | $4.44 M(+14.1%) |
| June 2003 | - | $1.18 M(+26.1%) | $3.89 M(+7.8%) |
| Mar 2003 | - | $933.40 K(+20.5%) | $3.61 M(-4.0%) |
| Dec 2002 | $3.76 M(+12.1%) | $774.40 K(-23.3%) | $3.76 M(-0.8%) |
| Sept 2002 | - | $1.01 M(+12.7%) | $3.80 M(+3.6%) |
| June 2002 | - | $895.70 K(-17.4%) | $3.66 M(+5.4%) |
| Mar 2002 | - | $1.08 M(+34.5%) | $3.48 M(+3.6%) |
| Dec 2001 | $3.36 M(+47.9%) | $806.50 K(-8.1%) | $3.36 M(+0.6%) |
| Sept 2001 | - | $877.60 K(+23.7%) | $3.34 M(+10.6%) |
| June 2001 | - | $709.50 K(-26.4%) | $3.02 M(+7.8%) |
| Mar 2001 | - | $964.10 K(+22.6%) | $2.80 M(+23.3%) |
| Dec 2000 | $2.27 M(+33.5%) | $786.10 K(+40.9%) | $2.27 M(+20.5%) |
| Sept 2000 | - | $557.90 K(+13.8%) | $1.88 M(+3.2%) |
| June 2000 | - | $490.20 K(+12.4%) | $1.83 M(+5.2%) |
| Mar 2000 | - | $436.10 K(+9.0%) | $1.74 M(+2.1%) |
| Dec 1999 | $1.70 M(+6.3%) | $400.00 K(-20.0%) | $1.70 M(0.0%) |
| Sept 1999 | - | $500.00 K(+25.0%) | $1.70 M(+6.3%) |
| June 1999 | - | $400.00 K(0.0%) | $1.60 M(-5.9%) |
| Mar 1999 | - | $400.00 K(0.0%) | $1.70 M(+6.3%) |
| Dec 1998 | $1.60 M(+23.1%) | $400.00 K(0.0%) | $1.60 M(0.0%) |
| Sept 1998 | - | $400.00 K(-20.0%) | $1.60 M(+6.7%) |
| June 1998 | - | $500.00 K(+66.7%) | $1.50 M(+7.1%) |
| Mar 1998 | - | $300.00 K(-25.0%) | $1.40 M(+7.7%) |
| Dec 1997 | $1.30 M(+116.7%) | $400.00 K(+33.3%) | $1.30 M(+44.4%) |
| Sept 1997 | - | $300.00 K(-25.0%) | $900.00 K(+50.0%) |
| June 1997 | - | $400.00 K(+100.0%) | $600.00 K(+200.0%) |
| Mar 1997 | - | $200.00 K | $200.00 K |
| Dec 1996 | $600.00 K | - | - |
FAQ
- What is Sarepta Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual SG&A year-on-year change?
- What is Sarepta Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly SG&A year-on-year change?
- What is Sarepta Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM SG&A year-on-year change?
What is Sarepta Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of SRPT is $481.87 M
What is the all time high annual SG&A for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual selling, general & administrative expenses is $481.87 M
What is Sarepta Therapeutics annual SG&A year-on-year change?
Over the past year, SRPT annual selling, general & administrative expenses has changed by +$30.45 M (+6.75%)
What is Sarepta Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of SRPT is $128.20 M
What is the all time high quarterly SG&A for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly selling, general & administrative expenses is $154.32 M
What is Sarepta Therapeutics quarterly SG&A year-on-year change?
Over the past year, SRPT quarterly selling, general & administrative expenses has changed by +$7.31 M (+6.04%)
What is Sarepta Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of SRPT is -$17.63 B
What is the all time high TTM SG&A for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM selling, general & administrative expenses is $525.70 M
What is Sarepta Therapeutics TTM SG&A year-on-year change?
Over the past year, SRPT TTM selling, general & administrative expenses has changed by -$18.10 B (-3845.88%)